| scholarly article | Q13442814 |
| P50 | author | Pier-Luigi Lollini | Q37838964 |
| Katia Scotlandi | Q57069898 | ||
| P2093 | author name string | Comoglio PM | |
| Cremona O | |||
| Baldini N | |||
| Campanacci M | |||
| Di Renzo MF | |||
| Olivero M | |||
| Ferracini R | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 739-749 | |
| P577 | publication date | 1995-02-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit | |
| P478 | volume | 10 |
| Q48270323 | 89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection |
| Q42821276 | A natural hepatocyte growth factor/scatter factor autocrine loop in myoblast cells and the effect of the constitutive Met kinase activation on myogenic differentiation |
| Q54445050 | A new drug in thoracic oncology: MetMab (onartuzumab) |
| Q47303095 | Activated HGF-c-Met Axis in Head and Neck Cancer |
| Q44510418 | Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin |
| Q35753150 | Activation of the Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor System and Redistribution of E-Cadherin Are Associated with Hepatocyte Growth Factor-Induced Motility of Pancreas Tumor Cells Overexpressing Met |
| Q42151554 | Alternative proteolytic processing of hepatocyte growth factor during wound repair |
| Q40810848 | An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential |
| Q35866739 | Aptamers Binding to c-Met Inhibiting Tumor Cell Migration |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q58165348 | C-met activation is necessary but not sufficient for liver colonization by B16 murine melanoma cells |
| Q36967334 | C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes |
| Q34533693 | Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas |
| Q74433027 | Co-expression of hepatocyte growth factor and its receptor in human prostate cancer |
| Q21245750 | Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma |
| Q47838353 | Constitutive Expression of HGF Modulates Renal Epithelial Cell Phenotype and Induces c-met and Fibronectin Expression |
| Q31062741 | Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 |
| Q90287282 | Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer |
| Q89823731 | Crosstalk Mechanisms Between HGF/c-Met Axis and ncRNAs in Malignancy |
| Q36868117 | DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma. |
| Q38433828 | Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation |
| Q33919211 | Differential expression of E-cadherin and beta catenin in primary and metastatic Wilms's tumours |
| Q33786959 | Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis |
| Q35961109 | Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor |
| Q42282846 | Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. |
| Q34584046 | Dysregulation of Met receptor tyrosine kinase activity in invasive tumors |
| Q36557528 | Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network |
| Q37355020 | ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. |
| Q33275985 | Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies |
| Q74453712 | Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid |
| Q35782214 | Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. |
| Q42912698 | Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling |
| Q37340499 | Genetic alterations in primary osteosarcoma from 54 children and adolescents by targeted allelotyping |
| Q42796734 | Growth Factor–dependent Activation of αvβ3 Integrin in Normal Epithelial Cells: Implications for Tumor Invasion |
| Q36641150 | HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice |
| Q77403442 | Hepatocyte Growth Factor and the Kidney: It Is Not Just for the Liver |
| Q26781273 | Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge |
| Q37430185 | Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. |
| Q41188806 | Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis |
| Q33863966 | Hepatocyte growth factor/scatter factor-induced intracellular signalling |
| Q39381922 | Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth |
| Q39405780 | In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs |
| Q38859217 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. |
| Q39816968 | Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling |
| Q35945084 | Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis |
| Q60909538 | MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk |
| Q38008247 | MET: a promising anticancer therapeutic target |
| Q92537377 | MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM |
| Q34085432 | Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression |
| Q53789447 | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy |
| Q36438319 | Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines |
| Q43201388 | Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture |
| Q33969327 | Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway |
| Q36803600 | Osteosarcoma development and stem cell differentiation |
| Q35742089 | Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer |
| Q42279434 | Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. |
| Q30917936 | PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells |
| Q36562114 | Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine |
| Q36696859 | Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation |
| Q24685493 | Preferential expression of RB1-inducible coiled-coil 1 in terminal differentiated musculoskeletal cells |
| Q34090139 | Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice |
| Q64077603 | Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase |
| Q35146597 | RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma |
| Q36398042 | Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1. |
| Q35217698 | Role of cancer cell-stroma interaction in invasive growth of cancer cells |
| Q47957999 | Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma |
| Q28212407 | Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition |
| Q36803657 | Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro |
| Q38197031 | Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies |
| Q37953076 | Targeted Agents for Sarcoma: Is Individualized Therapy Possible in Such a Diverse Tumor Type? |
| Q26781278 | Targeting RTK Signaling Pathways in Cancer |
| Q24609682 | The MET axis as a therapeutic target |
| Q34173500 | The Met oncogene and basal-like breast cancer: another culprit to watch out for? |
| Q35078950 | The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects |
| Q38085900 | The emerging role of MET/HGF inhibitors in oncology |
| Q35904618 | The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma |
| Q39594896 | The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model |
| Q35146937 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy |
| Q41660598 | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. |
| Q36194212 | Tumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion. |
| Q58760425 | Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications |
| Q28362076 | c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma |
| Q36731520 | c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy |
| Q47588979 | c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells |
| Q24337462 | hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas |
Search more.